Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EPS (Basic): 2023-2025

Historic EPS (Basic) for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$3.59.

  • Tonix Pharmaceuticals Holding's EPS (Basic) rose 84.17% to -$3.59 in Q3 2025 from the same period last year, while for Sep 2025 it was $279.28, marking a year-over-year increase of 101.64%. This contributed to the annual value of -$176.60 for FY2024, which is 98.80% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's EPS (Basic) is -$3.59, which was up 6.99% from -$3.86 recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's EPS (Basic) ranged from a high of $289.57 in Q4 2024 and a low of -$14,577 during Q4 2023.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median EPS (Basic) value was -$22.68 (recorded in 2024), while the average stood at -$1,868.
  • Data for Tonix Pharmaceuticals Holding's EPS (Basic) shows a peak YoY soared of 101.99% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's EPS (Basic) (Quarterly) stood at -$14,577 in 2023, then spiked by 101.99% to $289.57 in 2024, then spiked by 84.17% to -$3.59 in 2025.
  • Its EPS (Basic) was -$3.59 in Q3 2025, compared to -$3.86 in Q2 2025 and -$2.84 in Q1 2025.